Cannabinoid receptor 1–Adenosine A2A receptor–Dopamine D2 receptor heteromer (CB1–A2A–D2 heteromer)

The Cannabinoid receptor 1–Adenosine A2A receptor–Dopamine D2 receptor (CB1–A2A–D2) heteromer is a specialized macromolecular complex primarily located in the GABAergic medium spiny neurons of the striatum (Navarro et al., 2010, Blood). This trimeric assembly acts as a critical hub for integrating signals from the endocannabinoid, adenosinergic, and dopaminergic systems to regulate motor activity and reward-related behaviors (Ferré et al., 2009, British Journal of Pharmacology). Within this complex, the receptors exhibit reciprocal allosteric interactions; specifically, the activation of CB1 or A2A receptors negatively modulates the function of the D2 receptor, providing a molecular basis for the antagonistic effects of adenosine and cannabinoids on dopamine-mediated locomotion (Carriba et al., 2007, Neuropsychopharmacology). This heteromer is a significant therapeutic target for neurodegenerative and neuropsychiatric disorders, particularly Parkinson's disease, where modulating the complex could alleviate motor symptoms. Understanding the unique pharmacological properties of this heteromer allows for the development of heteromer-selective ligands that may offer improved efficacy and reduced side effects compared to drugs targeting the individual receptors (Marcellino et al., 2008, Journal of Neurochemistry).

Other names

CB1-A2A-D2 receptor complexCB1-A2A-D2 trimeric heteromerCNR1-ADORA2A-DRD2 heteromerCannabinoid-Adenosine-Dopamine receptor heteromer

Negative allosteric modulation where activation of CB1 or A2A receptors decreases the signaling efficacy and binding affinity of the D2 receptor within the complex.